Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study
Jia Jun Weng,*,1 Li Hua Wang,*,1 Hao Zhu,2 Wen Rong Xu,1 Yu Mei Wei,1 Zhi Yang Wang,1 Wen Juan Yu,1 Hua Fang Li1,3–41Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University of Medicine, Shanghai, People’s Republic of China; 2Department of Anesthesio...
Guardado en:
Autores principales: | Weng JJ, Wang LH, Zhu H, Xu WR, Wei YM, Wang ZY, Yu WJ, Li HF |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ae1f261d9a0849728efebc5889ba9b88 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
por: Hametner EM, et al.
Publicado: (2012) -
Restless legs syndrome: differential diagnosis and management with pramipexole
por: Francesca Brindani, et al.
Publicado: (2009) -
Apolipoprotein E e4 allele is associated with extrapyramidal symptoms in Alzheimer’s disease
por: Chang YP, et al.
Publicado: (2019) -
Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report
por: Igata R, et al.
Publicado: (2016) -
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018)